Pembrolizumab 200 mg
3475-365
Phase 2 mab active
Quick answer
Pembrolizumab 200 mg for Metastatic Castration-Resistant Prostate Cancer is a Phase 2 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Metastatic Castration-Resistant Prostate Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- active